Novo Nordisk A/S (NYSE:NVO) Rating Increased to Buy at UBS Group

UBS Group upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a sell rating to a buy rating in a report issued on Wednesday,Benzinga reports.

A number of other brokerages also recently commented on NVO. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $85.63 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market capitalization of $384.27 billion, a P/E ratio of 27.71, a P/E/G ratio of 1.37 and a beta of 0.45. The company’s 50-day simple moving average is $101.38 and its two-hundred day simple moving average is $120.03. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors have recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Abound Wealth Management lifted its stake in shares of Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the period. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $42,000. Finally, Carolina Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $48,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.